JP2007523178A5 - - Google Patents

Download PDF

Info

Publication number
JP2007523178A5
JP2007523178A5 JP2006554231A JP2006554231A JP2007523178A5 JP 2007523178 A5 JP2007523178 A5 JP 2007523178A5 JP 2006554231 A JP2006554231 A JP 2006554231A JP 2006554231 A JP2006554231 A JP 2006554231A JP 2007523178 A5 JP2007523178 A5 JP 2007523178A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
treatment
agent according
disorders
mglur5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006554231A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007523178A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/005200 external-priority patent/WO2005080379A1/en
Publication of JP2007523178A publication Critical patent/JP2007523178A/ja
Publication of JP2007523178A5 publication Critical patent/JP2007523178A5/ja
Pending legal-status Critical Current

Links

JP2006554231A 2004-02-18 2005-02-17 代謝型グルタメート受容体アンタゴニストとしてのトリアゾール化合物およびそれらの使用 Pending JP2007523178A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54528904P 2004-02-18 2004-02-18
PCT/US2005/005200 WO2005080379A1 (en) 2004-02-18 2005-02-17 Triazole compounds and their use as metabotropic glutamate receptor antagonists

Publications (2)

Publication Number Publication Date
JP2007523178A JP2007523178A (ja) 2007-08-16
JP2007523178A5 true JP2007523178A5 (enExample) 2008-03-27

Family

ID=34886127

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006554231A Pending JP2007523178A (ja) 2004-02-18 2005-02-17 代謝型グルタメート受容体アンタゴニストとしてのトリアゾール化合物およびそれらの使用

Country Status (17)

Country Link
US (2) US20070185178A1 (enExample)
EP (1) EP1720860A1 (enExample)
JP (1) JP2007523178A (enExample)
KR (1) KR20070027503A (enExample)
CN (1) CN101018779A (enExample)
AR (1) AR047744A1 (enExample)
AU (1) AU2005214375A1 (enExample)
BR (1) BRPI0507501A (enExample)
CA (1) CA2554894A1 (enExample)
EA (1) EA200601266A1 (enExample)
IL (1) IL177057A0 (enExample)
NO (1) NO20063468L (enExample)
RU (1) RU2006127575A (enExample)
TW (1) TW200604183A (enExample)
UY (1) UY28760A1 (enExample)
WO (1) WO2005080379A1 (enExample)
ZA (1) ZA200606313B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006080533A1 (ja) * 2005-01-31 2006-08-03 Mochida Pharmaceutical Co., Ltd. 3-アミノ-1,2,4-トリアゾール誘導体
UY29796A1 (es) 2005-09-29 2007-04-30 Astrazeneca Ab Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
TW200811156A (en) * 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators IV
KR20100090777A (ko) 2007-10-19 2010-08-17 아스트라제네카 아베 대사성 글루타메이트 수용체 (mglur)의 조절제로서의 테트라졸 유도체
CN101918399A (zh) * 2007-10-26 2010-12-15 阿斯利康(瑞典)有限公司 作为mglur5调节剂的氨基1,2,4-三唑衍生物
WO2009054785A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab 1,2,4-triazole ether derivatives as modulators of mglur5
WO2009054790A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab Amide linked heteroaromatic derivatives as modulators of mglur5
CN101643451B (zh) * 2008-08-07 2013-03-06 浙江海正药业股份有限公司 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法
US20100114146A1 (en) * 2008-10-30 2010-05-06 Albrecht Thomas E Methods and devices for predicting intra-gastric satiety and satiation creation device system performance
JP2012511570A (ja) * 2008-12-12 2012-05-24 アストラゼネカ・アクチエボラーグ 4−[4−メチル−5−(c1−10アルキルチオ/c5−10アリール−c1−6アルキルチオ)−4h−1,2,4−トリアゾール−3−イル]ピリジンの新規製造方法
CN102256967A (zh) * 2008-12-18 2011-11-23 阿斯利康(瑞典)有限公司 制备3-{4-甲基-5-[(1r)-1-(2-(3-甲基苯基-2h-四唑-5-基)-乙氧基]-4h-[1,2,4]三唑-3-基}-吡啶、4-甲基-3-甲基硫基-5-(吡啶-3-基)-1,2,4-三唑和(1r)-1-[2-(3-甲基苯基)-2h-四唑-5-基]乙醇的方法
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US20100273805A1 (en) * 2009-04-23 2010-10-28 Astrazeneca Ab Sulphide bridged derivatives as modulators of mglur5 733
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
BR112013011265A2 (pt) * 2010-11-09 2016-11-01 Hoffmann La Roche derivados de triazol como ligantes para receptores gaba
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
US9676754B2 (en) 2012-12-20 2017-06-13 Inception 2, Inc. Triazolone compounds and uses thereof
PE20160880A1 (es) 2013-09-06 2016-09-22 Inception 2 Inc Compuestos de triazolona y usos de los mismos
JP6483666B2 (ja) 2013-10-14 2019-03-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 選択的に置換されたキノリン化合物
WO2015057659A1 (en) 2013-10-14 2015-04-23 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
US10155727B2 (en) 2014-08-15 2018-12-18 Janssen Pharmaceuticals, Inc. Pyrazoles
HUE049277T2 (hu) 2014-08-15 2020-09-28 Janssen Pharmaceuticals Inc Triazolok mint NR2B receptor inhibitorok
HRP20200410T1 (hr) 2015-07-09 2020-08-21 Janssen Pharmaceutica Nv Supstituirani 4-azaindoli i njihova upotreba kao modulatora glun2b receptora
KR20180108822A (ko) 2016-02-10 2018-10-04 얀센 파마슈티카 엔.브이. Nr2b-선택적 nmda 조절제로서 치환된 1,2,3-트라이아졸
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途
US11247987B2 (en) 2017-10-06 2022-02-15 Forma Therapeutics, Inc. Inhibiting ubiquitin specific peptidase 30
EP3774732A4 (en) 2018-04-04 2022-02-09 Janssen Pharmaceutica NV PYRIDINE AND SUBSTITUTED PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
IL278291B2 (en) 2018-05-17 2023-10-01 Forma Therapeutics Inc Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors
LT3860989T (lt) 2018-10-05 2023-06-12 Forma Therapeutics, Inc. Sulieti pirolinai, kurie veikia kaip ubikvitinui specifinės proteazės 30 (ups30) inhibitoriai
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
MX2021015506A (es) 2019-06-14 2022-02-10 Janssen Pharmaceutica Nv Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b.
CA3143102A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted pyrazolo[4,3-b]pyridines and their use as glun2b receptor modulators
SG11202112405VA (en) 2019-06-14 2021-12-30 Janssen Pharmaceutica Nv Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
EP3983074A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Pyridine carbamates and their use as glun2b receptor modulators
CN113950357A (zh) 2019-06-14 2022-01-18 詹森药业有限公司 吡嗪氨基甲酸酯及其作为GluN2B受体调节剂的用途
JP7667097B2 (ja) 2019-06-14 2025-04-22 ヤンセン ファーマシューティカ エヌ.ベー. 置換ピラゾロ-ピリジンアミド及びglun2b受容体調節因子としてのその使用
MX2021015500A (es) 2019-06-14 2022-02-10 Janssen Pharmaceutica Nv Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b.
CN110669017B (zh) * 2019-10-11 2023-08-04 成都麻沸散医药科技有限公司 多取代三唑甲酸酯类衍生物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE396186T1 (de) * 2001-10-04 2008-06-15 Merck & Co Inc Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5
DE60235114D1 (de) * 2001-11-01 2010-03-04 Icagen Inc Pyrazolamide zur anwendung in der behandlung von schmerz
US7592337B2 (en) * 2002-03-12 2009-09-22 Merck & Co., Inc. Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
PL375256A1 (en) * 2002-08-09 2005-11-28 Astra Zeneca Ab 1,2,4-oxadiazoles as modulators of metabotropic glutamate receptor-5
AU2003264018A1 (en) * 2002-08-09 2004-02-25 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors

Similar Documents

Publication Publication Date Title
JP2007523178A5 (enExample)
ZA200802872B (en) Combination therapy comprising substituted oxazolidinones for the prevention and treatment of cerebral circulatory disorders
IL191311A (en) Transdermal therapeutic system and its use in the preparation of drugs for the prevention, treatment or delay of the progression of Alzheimer's disease, Parkinson's disease-related dementia and symptoms of traumatic brain injury
EP1895959A4 (en) POLYTHERAPY FOR THE TREATMENT OF IMMUNO-INFLAMMATORY DISORDERS
IL184371A (en) Use of an anti il-31ra antibody in the manufacture of a medicament for treating skin disorders
IL181706A0 (en) The treatment of inflammatory disorders and pain
NO20053678D0 (no) Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser
IL191245A0 (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
JP2007536277A5 (enExample)
JP2006514116A5 (enExample)
GB0410398D0 (en) The treatment of respiratory disease
WO2007075592A3 (en) Materials and methods for treating chronic fibrotic disease
IL195441A0 (en) Use of trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthaleneamine and its formamide in the preparation of medicaments for the treatment of pain disorders
ZA200607531B (en) Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorders in the depressed patient
WO2007009701A3 (en) Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
JP2008519810A5 (enExample)
PL1865966T3 (pl) Zastosowanie niesteroidowych leków przeciwzapalnych do inhalacji w leczeniu ostrego i chronicznego zapalenia oskrzeli
JP2009523124A5 (enExample)
RU2005119153A (ru) Средство лечения острой лучевой болезни
JP2006501269A5 (enExample)
TWI318115B (en) Use of agomelatine in obtaining medicaments intended for the treatment of bipolar disorders
GB0419828D0 (en) The treatment of inflammatroy disorders and pain
EP1867340A4 (en) THERAPEUTIC AGENT FOR TREATING DISEASES IN THE BOVINE DIGESTIVE SYSTEM
JP2005516073A5 (enExample)
JP2008520625A5 (enExample)